BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li Y, Ma Y, Wu Z, Zeng F, Song B, Zhang Y, Li J, Lui S, Wu M. Tumor Mutational Burden Predicting the Efficacy of Immune Checkpoint Inhibitors in Colorectal Cancer: A Systematic Review and Meta-Analysis. Front Immunol 2021;12:751407. [PMID: 34659255 DOI: 10.3389/fimmu.2021.751407] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 San-román-gil M, Torres-jiménez J, Pozas J, Esteban-villarrubia J, Albarrán-fernández V, Álvarez-ballesteros P, Chamorro-pérez J, Rosero-rodríguez D, Orejana-martín I, Martínez-delfrade Í, Reguera-puertas P, Fuentes-mateos R, Ferreiro-monteagudo R. Current Landscape and Potential Challenges of Immune Checkpoint Inhibitors in Microsatellite Stable Metastatic Colorectal Carcinoma. Cancers 2023;15:863. [DOI: 10.3390/cancers15030863] [Reference Citation Analysis]
2 Tan L, Li QS, Peng D, Cheng Y. Does PD-1 blockade play a decisive role in the pathological complete remission of unresectable MSS, BRAF V600E-mutated metastatic colorectal cancer: A case report. Front Oncol 2022;12:976622. [PMID: 36713544 DOI: 10.3389/fonc.2022.976622] [Reference Citation Analysis]
3 Deng X, Liu X, Hu B, Liu J, Fu B, Zhang W. Upregulation of MTHFD2 is associated with PD‑L1 activation in bladder cancer via the PI3K/AKT pathway. Int J Mol Med 2023;51:14. [PMID: 36601741 DOI: 10.3892/ijmm.2022.5217] [Reference Citation Analysis]
4 Lyu C, Wang L, Stadlbauer B, Buchner A, Pohla H. A Pan-Cancer Landscape of ABCG2 across Human Cancers: Friend or Foe? Int J Mol Sci 2022;23. [PMID: 36555598 DOI: 10.3390/ijms232415955] [Reference Citation Analysis]
5 Ke L, Li S, Cui H. The prognostic role of tumor mutation burden on survival of breast cancer: a systematic review and meta-analysis. BMC Cancer 2022;22:1185. [DOI: 10.1186/s12885-022-10284-1] [Reference Citation Analysis]
6 Ke L, Li S, Cui H. The Predictive Effect of Tumor Mutation Burden on prognosis in Breast cancer: A Systematic Review and Meta-Analysis.. [DOI: 10.21203/rs.3.rs-2043934/v1] [Reference Citation Analysis]
7 Yang S, Zhao S, Ye Y, Jia L, Lou Y. Global research trends on the links between gut microbiota and cancer immunotherapy: A bibliometric analysis (2012-2021). Front Immunol 2022;13:952546. [DOI: 10.3389/fimmu.2022.952546] [Reference Citation Analysis]
8 Damato A, Rotolo M, Caputo F, Borghi E, Iachetta F, Pinto C. New Potential Immune Biomarkers in the Era of Precision Medicine: Lights and Shadows in Colorectal Cancer. Life (Basel) 2022;12:1137. [PMID: 36013315 DOI: 10.3390/life12081137] [Reference Citation Analysis]
9 Liu Y, Fu S, Zhang Z, Wang S, Cheng X, Li Z, Ding Y, Sun T, Ma M, Glavac D. GRAMD1A Is a Biomarker of Kidney Renal Clear Cell Carcinoma and Is Associated with Immune Infiltration in the Tumour Microenvironment. Disease Markers 2022;2022:1-25. [DOI: 10.1155/2022/5939021] [Reference Citation Analysis]
10 Han J, Hu Y, Liu S, Jiang J, Wang H, Pan J. A Newly Established Cuproptosis-Associated Long Non-Coding RNA Signature for Predicting Prognosis and Indicating Immune Microenvironment Features in Soft Tissue Sarcoma. Journal of Oncology 2022;2022:1-27. [DOI: 10.1155/2022/8489387] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
11 Xiang L, Lan C. Significance of a Tumor Mutation Burden Gene Signature with Prognosis and Immune Feature of Gastric Cancer Patients. Int J Genomics 2022;2022:7684606. [PMID: 35719415 DOI: 10.1155/2022/7684606] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
12 Long AH, Morgenstern DA, Leruste A, Bourdeaut F, Davis KL. Checkpoint Immunotherapy in Pediatrics: Here, Gone, and Back Again. Am Soc Clin Oncol Educ Book 2022;42:1-14. [PMID: 35580293 DOI: 10.1200/EDBK_349799] [Reference Citation Analysis]